Ciaftalan

Ciaftalan

SCHEMBL29360952

c1ccc2c(c1)-c1nc-2nc2[nH]c(nc3nc(nc4[nH]c(n1)c1ccccc41)-c1ccccc1-3)c1ccccc21

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.46
KMT2A Q03164 4/20 0.46
TDP1 Q9NUW8 4/20 0.46
RECQL P46063 2/20 0.46
THRB P10828 1/20 0.46
APEX1 P27695 1/20 0.46
BLM P54132 1/20 0.46
CA5A P35218 1/20 0.41
HSD17B10 Q99714 4/20 0.36
CYP1A2 P05177 3/20 0.36
CYP3A4 P08684 3/20 0.36
CYP2D6 P10635 3/20 0.36
CYP2C19 P33261 3/20 0.36
USP2 O75604 1/20 0.36
ALOX15 P16050 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
ALDH1A1 P00352 4/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MAPK1 P28482 3/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ciaftalan SCHEMBL15816 1.00 MEN1 (0.46) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL29356273 1.00 MEN1 (0.46) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL5795179 1.00 MEN1 (0.46) MEN1KMT2ATDP1RECQLTHRB
SCHEMBL813083 1.00 MEN1 (0.46) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL1728179 1.00 MEN1 (0.46) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL3199060 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL11430027 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL6550047 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL15992891 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB
Ciaftalan SCHEMBL22471714 0.98 MEN1 (0.45) MEN1KMT2ATDP1RECQLTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025133713-A1 SYSTEM FOR DIGITAL TRANSFER PRINTING ON LIGHT OR DARK TEXTILE SUBSTRATES AND TRANSFER METHOD SUMIPRINT QUIMICA Y COLOR S.A.S. (CO) 2025-06-26 WO claimed
WO-2025035196-A1 MOISTURISING CREAM WITH LONG-LASTING ANTISEPTIC PROTECTION FOR HANDS USE PHITTA CREAM LTDA - EPP (BR) 2025-02-20 WO claimed
WO-2024110685-A1 SENSOR FOR DETECTING MERCAPTANS IN WINES AND METHOD FOR DETERMINING SAME UNIVERSIDAD DE BURGOS (ES) 2024-05-30 WO claimed
WO-2024094911-A1 BIODEGRADABLE ELASTOMERS AND METHOD FOR OBTAINING SAME CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2024-05-10 WO claimed
CN-115006582-B Anti-inflammatory and antioxidant nano dressing and preparation method thereof 南通大学 2023-06-02 CN claimed
US-12514310-B2 Damage-resistant gloves with breach-indicator function SMARTERIALS TECHNOLOGY GMBH (DE) 2026-01-06 US disclosed
WO-2025133713-A1 SYSTEM FOR DIGITAL TRANSFER PRINTING ON LIGHT OR DARK TEXTILE SUBSTRATES AND TRANSFER METHOD SUMIPRINT QUIMICA Y COLOR S.A.S. (CO) 2025-06-26 WO disclosed
WO-2025039049-A1 HIGH DEGASSING POWDER PAINT AND METHOD OF OBTAINING A HIGH DEGASSING POWDER PAINT PAUMAR S.A. — INDÚSTRIA E COMÉRCIO (BR) 2025-02-27 WO disclosed
WO-2025035196-A1 MOISTURISING CREAM WITH LONG-LASTING ANTISEPTIC PROTECTION FOR HANDS USE PHITTA CREAM LTDA - EPP (BR) 2025-02-20 WO disclosed
WO-2025035196-A1 MOISTURISING CREAM WITH LONG-LASTING ANTISEPTIC PROTECTION FOR HANDS USE PHITTA CREAM LTDA - EPP (BR) 2025-02-20 WO disclosed
US-20240424147-A1 PHTHALOCYANINE-LOADED MICELLES FOR THE DIRECT VISUALIZATION OF TUMORS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2024-12-26 US disclosed
US-12138309-B2 Topical formulations containing phthalocyanine photosensitizers MOLTENI THERAPEUTICS S.R.L. (IT) 2024-11-12 US disclosed
EP-4039338-A1 ORAL-HEALTH COMPOSITION AND PREPARATION METHOD FOR ORAL-HEALTH COMPOSITION MMF&T Desenvolvimento Tecnológico e Inovação Ltda. (BR) 2022-08-10 EP disclosed
EP-3526274-B1 CATALYST SYSTEM EPC ENGINEERING & TECH GMBH (DE) 2022-08-03 EP disclosed
US-20220233696-A1 TOPICAL FORMULATIONS CONTAINING PHTHALOCYANINE PHOTOSENSITIZERS L. MOLTENI & C. DEI FRATELLI ALITTI – SOCIETA’ DI ESERCIZIO - S.P.A (IT) 2022-07-28 US disclosed
US-11384033-B2 Compositions with improved urease-inhibiting effect comprising (thio)phosphoric acid triamide and further compounds such as amines and colorants BASF SE (DE) 2022-07-12 US disclosed
WO-2022064090-A2 SOLVENT-BASED INKS AND COATINGS FOR FOOD CONTACT APPLICATIONS SUN CHEMICAL CORPORATION (US) 2022-03-31 WO disclosed
WO-2022036467-A1 SELF-ADHESIVE FILM AND SHEET HAVING AN ANTIBACTERIAL AND ANTIVIRAL COATING ON ONE SIDE GUERRERO CARO JOSE LUIS (CL) 2022-02-24 WO disclosed
CN-110234483-B Damage-resistant glove with notch indication function 智能材料科技有限公司 2022-01-28 CN disclosed
WO-2022018316-A1 HEAT-CURABLE AQUEOUS DYES FOR INKJET PRINTING SUN CHEMICAL CORPORATION (US) 2022-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12138309-B2 Topical formulations containing phthalocyanine photosensitizers SLC30A5, SLC39A3, SLC39A11 MEN1 3318/4885KMT2A 2168/4885TDP1 3407/4885
US-20220233696-A1 TOPICAL FORMULATIONS CONTAINING PHTHALOCYANINE PHOTOSENSITIZERS SLC30A5, SLC39A3, SLC39A11 MEN1 3318/4885KMT2A 2168/4885TDP1 3407/4885
US-11384033-B2 Compositions with improved urease-inhibiting effect comprising (thio)phosphoric acid triamide and further compounds such as amines and colorants SLC14A1, XDH, PNP MEN1 4263/4885KMT2A 2627/4885TDP1 2532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.